437 related articles for article (PubMed ID: 16326714)
1. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists.
Nawrocki AR; Rajala MW; Tomas E; Pajvani UB; Saha AK; Trumbauer ME; Pang Z; Chen AS; Ruderman NB; Chen H; Rossetti L; Scherer PE
J Biol Chem; 2006 Feb; 281(5):2654-60. PubMed ID: 16326714
[TBL] [Abstract][Full Text] [Related]
2. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
[TBL] [Abstract][Full Text] [Related]
3. Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance.
Amin RH; Mathews ST; Camp HS; Ding L; Leff T
Am J Physiol Endocrinol Metab; 2010 Jan; 298(1):E28-37. PubMed ID: 19843873
[TBL] [Abstract][Full Text] [Related]
4. Kaempferia parviflora Ethanol Extract, a Peroxisome Proliferator-Activated Receptor γ Ligand-binding Agonist, Improves Glucose Tolerance and Suppresses Fat Accumulation in Diabetic NSY Mice.
Ochiai M; Takeuchi T; Nozaki T; Ishihara KO; Matsuo T
J Food Sci; 2019 Feb; 84(2):339-348. PubMed ID: 30726580
[TBL] [Abstract][Full Text] [Related]
5. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
Norris AW; Chen L; Fisher SJ; Szanto I; Ristow M; Jozsi AC; Hirshman MF; Rosen ED; Goodyear LJ; Gonzalez FJ; Spiegelman BM; Kahn CR
J Clin Invest; 2003 Aug; 112(4):608-18. PubMed ID: 12925701
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.
Kubota N; Terauchi Y; Kubota T; Kumagai H; Itoh S; Satoh H; Yano W; Ogata H; Tokuyama K; Takamoto I; Mineyama T; Ishikawa M; Moroi M; Sugi K; Yamauchi T; Ueki K; Tobe K; Noda T; Nagai R; Kadowaki T
J Biol Chem; 2006 Mar; 281(13):8748-55. PubMed ID: 16431926
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies.
Haluzik M; Gavrilova O; LeRoith D
Endocrinology; 2004 Apr; 145(4):1662-7. PubMed ID: 14670996
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance.
Odegaard JI; Ricardo-Gonzalez RR; Goforth MH; Morel CR; Subramanian V; Mukundan L; Red Eagle A; Vats D; Brombacher F; Ferrante AW; Chawla A
Nature; 2007 Jun; 447(7148):1116-20. PubMed ID: 17515919
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
[TBL] [Abstract][Full Text] [Related]
10. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats.
Yang B; Brown KK; Chen L; Carrick KM; Clifton LG; McNulty JA; Winegar DA; Strum JC; Stimpson SA; Pahel GL
BMC Pharmacol; 2004 Oct; 4():23. PubMed ID: 15491498
[TBL] [Abstract][Full Text] [Related]
11. Changes in adiponectin and inflammatory genes in response to hormonal imbalances in female mice and exacerbation of depot selective visceral adiposity by high-fat diet: implications for insulin resistance.
Zhang H; Chen X; Aravindakshan J; Sairam MR
Endocrinology; 2007 Dec; 148(12):5667-79. PubMed ID: 17717050
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?
Bouskila M; Pajvani UB; Scherer PE
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S17-23. PubMed ID: 15711577
[TBL] [Abstract][Full Text] [Related]
13. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance.
Jones JR; Barrick C; Kim KA; Lindner J; Blondeau B; Fujimoto Y; Shiota M; Kesterson RA; Kahn BB; Magnuson MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6207-12. PubMed ID: 15833818
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
[TBL] [Abstract][Full Text] [Related]
15. WSF-7 Inhibits Obesity-Mediated PPARγ Phosphorylation and Improves Insulin Sensitivity in 3T3-L1 Adipocytes.
Zhang Y; Wang Y; Li X; Gu K; Li M; Zhang Y; Zhang Z; Wang S; Li Z
Biol Pharm Bull; 2020; 43(3):526-532. PubMed ID: 32115511
[TBL] [Abstract][Full Text] [Related]
16. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
17. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
18. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
[TBL] [Abstract][Full Text] [Related]
19. New PPARγ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr(-/-) mice.
Silva JC; César FA; de Oliveira EM; Turato WM; Tripodi GL; Castilho G; Machado-Lima A; de Las Heras B; Boscá L; Rabello MM; Hernandes MZ; Pitta MG; Pitta IR; Passarelli M; Rudnicki M; Abdalla DS
Pharmacol Res; 2016 Feb; 104():49-60. PubMed ID: 26706782
[TBL] [Abstract][Full Text] [Related]
20. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Zierath JR; Ryder JW; Doebber T; Woods J; Wu M; Ventre J; Li Z; McCrary C; Berger J; Zhang B; Moller DE
Endocrinology; 1998 Dec; 139(12):5034-41. PubMed ID: 9832442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
